Characteristics and outcomes of revascularized patients with hypertension an International Verapamil SR-Trandolapril substudy

Hypertension

Volumn 53, Issue 4, 2009, Pages 624-630

  Denardo, Scott J ^a,e,f   Messerli, Franz H ^a   Gaxiola, Efrain ^d   Aranda Jr , Juan M ^a   Cooper Dehoff, Rhonda M ^a   Handberg, Eileen M ^c   Gong, Yan ^b   Champion, Annette ^e   Zhou, Qian ^e   Pepine, Carl J ^a  

^a Departments of Epidemiology Population Health and Psychiatry Behavioral Sciences Albert Einstein   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d HOSPITAL DE ESPECIALIDADES   (Mexico)

^e ABBOTT LABORATORIES   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Blood pressure; Coronary artery bypass grafting; Coronary artery disease; Epidemiology; Hypertension; Percutaneous coronary intervention; Revascularization

Indexed keywords

ATENOLOL; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; INDOLES; MALE; MIDDLE AGED; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERAPAMIL;

EID: 64849110071     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.111542     Document Type: Article

References (22)

1. Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston, MA: Harvard School of Public Health; 1996.
2. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thorn T, Wasserthiel-Smoller S, Hong Y, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-el71.
3. Nicholls SJ, Tuzcu EM, Crowe T, Sipahi I, Schoenhagen P, Kapadia S, Hazen SL, Wun CC, Norton M, Ntanios F, Nissen SE. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006;47: 1967-1975.
4. Pepine CJ, Abrams J, Marks RG, Morris JJ, Scheidt SS, Handberg E, for the TIDES Investigators. Characteristics of a contemporary population with angina pectoris. Am J Cardiol. 1994;74:226-231.
5. Kanavos P, Ostergren J, Weber, MA, eds. High Blood Pressure and Health Policy: Where We Are and Where We Need to Go Next; A Global Assessment of Current Efforts to Control High Blood Pressure and an Analysis of Future Options to Prevent a Silent Epidemic Affecting Hundreds of Millions Worldwide. New York, NY: Ruder Finn; 2007. Available at: http://www.nature.com/isn/media/High- Blood-Pressure-and-Health-Policy.pdf. Accessed August 27, 2007.
6. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107:2900-2907.
7. Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Batlles D, Brunken RC, Fromm B. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116:997-1004.
8. Hochman JS, Sleeper LA, White HD, Dzavik V, Wong SC, Menon V, Webb JG, Steingart R, Picard MH, Menegus MA, Boland J, Sanborn T, Buller CE, Modur S, Forman R, Desvigne-Nickens P, Jacobs AK, Slater JN, LeJemtel TH, for the SHOCK Investigators. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285: 190-192.
9. Boersma E, Mercado N, Poldermans D, Gardien M, Vos J, Simoons ML. Acute myocardial infarction. Lancet. 2003;361:847-858.
10. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper- DeHoff R, Volkers P, Zellig P. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST) : an internet-based randomized trial in coronary artery disease patients with hypertension. J Am Coll Cardiol. 1998;32:1228-1237.
11. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW, for the INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST) : a randomized controlled trial. JAMA. 2003;29:2805-2816.
12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
13. Summary of the second report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
14. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation. 2007;115:2340-2343.
16. Hannan EL, Racz MJ. Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isorn OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med. 2005;352:2174-2183.
17. Serruys PW, Ong AT, van Herwerden LA, Sousa JE, Jatene A, Bonnier JJ, Schonberger JP, Buller N, Bonser R, Disco C, Backx B, Hugenholtz PG, Firth BG, Unger F. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease. The final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575-581.
18. Bestehorn HP. Neumann FJ, Büttner HJ, Betz P, Stürzenhofecker P, von Hodenberg E, Verdun A, Levai L, Monassier JP, Roskamm H. Evaluation of the effect of oral verapamil on clinical outcome and angiographic restenosis after percutaneous coronary intervention. The randomized, double-blind, placebo-controlled, multicenter Verapamil Slow-Release for Prevention of Cardiovascular Events After Angioplasty (VESPA) Trial. J Am Coll Cardiol. 2004;43:2160-2165.
19. Dens J, Desmet W, Piessens J. An updated meta-analysis of calciumchannel blockers in the prevention of restenosis after coronary angioplasty. Am Heart J. 2003;145:404-408.
20. Jackson JD, Muhlestein JE, Bunch TJ, Bair TL, Home BD, Madsen TE, Lappé JM, Anderson JL, for the Intermountain Heart Collaborative Study Group. Beta-blockers reduce the incidence of clinical restenosis: prospective study of 4840 patients undergoing percutaneous coronary revascularization. Am Heart J. 2003;145:875-881.
21. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A. Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous9 Ann Intern Med. 2006;144:884-893.
22. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL Jr. Kaplan NM, O'Connor CM. O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association council for high blood pressure research and the councils on clinical cardiology and epidemiology and prevention. Circulation. 2007;115:2761-2788.